Opening a new era in neurology

BrainTale biomarkers’ potential has been demonstrated in selected myelopathies notably adrenoleukodystrophy (ALD).1

ALD affects 1/15000 patients EU and US and is a life-threatening disease where no therapeutic option  is available today.2 

BrainTale can support drug developers and clinicians to take the appropriate decision of patients’ inclusion, early diagnostic,  disease monitoring and follow-up.

References

1Köhler, W., Engelen, M., Eichler, F., Lachmann, R., Fatemi, A., Sampson, J., … & Hashmi, S. (2023). Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2–3 trial. The Lancet Neurology, 22(2), 127-136.

2 Moser, A. B., Jones, R. O., Hubbard, W. C., Tortorelli, S., Orsini, J. J., Caggana, M., … & Raymond, G. V. (2016). Newborn screening for X-linked adrenoleukodystrophy. International journal of neonatal screening, 2(4), 15.

 

Legal disclaimer:

  • BRAINTALE, whose head office is 11 rue de l’Académie 67000 – STRASBOURG, is registered in the Trade and Companies Register under number 840 995 138 RCS STRASBOURG
  • – Manufacturer address: 140 rue du Chevaleret, 75013 Paris

 

Mandatory statement:

  • BrainTale-care is a Class IIa medical device
  • Notified body : BSI Netherlands 2797
  • This information deals with brainTale-care platform and modules (brainQuant and brainScore-coma). We invite you to read carefully the instructions for use and the label.
  • BrainTale-care is not reimbursed by social security.
  • BrainTale is ISO 13485 certified company

 

Last update : 12/18/2023